BeStock  
Stocks › Biotechnology › PHAT

Phathom Pharmaceuticals PHAT

US equityMarket cap rank #3686Biotechnology
$4.66 −$0.42 (-8.27%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $4.66 0.00%
Open$4.93
Prev close$5.08
Day range$4.62 – $5.15
Volume1.33M
Market cap$378.82M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$84.72M+71.1% YoY
Operating profit-$85,000.00+99.4% YoY
Net profit-$13.90M+53.6% YoY
Diluted EPS-$0.16+61.0% YoY
Free cash flow$1.73M+112.2% YoY
Operating cash flow$1.84M

Revenue, last 8 quarters

$29.7MDec '24$28.5MMar '25$39.5MJun '25$49.5MSep '25$57.6MDec '25$58.3MMar '26$74.3MJun '26$84.7MSep '26

Net profit, last 8 quarters

$-74.5MDec '24$-94.3MMar '25$-75.8MJun '25$-30.0MSep '25$-21.1MDec '25$-30.4MMar '26$-17.6MJun '26$-13.9MSep '26

Diluted EPS by quarter

-1.05Dec '24-1.31Mar '25-1.05Jun '25-0.41Sep '25-0.29Dec '25-0.37Mar '26-0.21Jun '26-0.16Sep '26

Free cash flow by quarter

$-63.5MDec '24$-84.9MMar '25$-62.8MJun '25$-14.1MSep '25$-5.1MDec '25$-15.7MMar '26$-2.0MJun '26$1.7MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$682.0KFY23$55.3MFY24$175.1MFY25

Profitability & balance sheet

Gross margin80.7%
Operating margin-9.3%
Net margin-30.2%
Return on assets-28.4%
Current ratio1.76
Liabilities / assets200.8%
Cash & investments$184.56M
Total debt$167.28M
Net cash (debt)$17.27M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $84.72M $74.27M $58.30M $175.11M $57.58M
Total Operating Revenue $84.72M $74.27M $58.30M $175.11M $57.58M
Cost of Revenue $18.37M $15.10M $12.00M $22.60M $7.65M
Gross Profit $66.36M $59.18M $46.31M $152.51M $49.94M
Operating Expense $66.44M $63.14M $61.78M $312.50M $55.86M
Selling and Admin Expenses $57.70M $55.33M $54.01M $279.72M $48.37M
Research & Development $8.75M $7.81M $7.77M $32.78M $7.49M
Operating Profit -$85,000.00 -$3.97M -$15.48M -$159.99M -$5.93M
Net Non-Operating Interest Income (Expense) -$13.79M -$13.59M -$14.06M -$61.07M -$15.22M
Non-Operating Interest Income $1.60M $1.51M $1.74M $7.04M $1.20M
Non-Operating Interest Expense $15.39M $15.10M $15.80M $68.12M $16.42M
Other Income (Expense) -$25,000.00 -$24,000.00 -$831,000.00 -$190,000.00 -$5,000.00
Other Non-Operating Income (Expenses) -$25,000.00 -$24,000.00 -$831,000.00 -$190,000.00 -$5,000.00
Pretax Profit -$13.90M -$17.58M -$30.37M -$221.25M -$21.15M
Net Profit -$13.90M -$17.58M -$30.37M -$221.25M -$21.15M
Profit from Continuing Operations -$13.90M -$17.58M -$30.37M -$221.25M -$21.15M
Net Income to Parent Company -$13.90M -$17.58M -$30.37M -$221.25M -$21.15M
Net Income to Common Stockholders -$13.90M -$17.58M -$30.37M -$221.25M -$21.15M
Basic EPS -$0.16 -$0.21 -$0.37 -$3.03 -$0.29
Diluted EPS -$0.16 -$0.21 -$0.37 -$3.03 -$0.29

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $345.02M $327.08M $305.12M $259.15M $259.15M
Total Current Assets $308.01M $295.92M $276.57M $228.97M $228.97M
Cash and Cash Equivalents & Short-Term Investments $184.56M $182.48M $180.90M $129.97M $129.97M
-Cash and Cash Equivalents $184.56M $182.48M $180.90M $129.97M $129.97M
Receivables $107.60M $97.42M $80.72M $78.13M $78.13M
-Accounts Receivable $107.60M $97.42M $80.72M $78.13M $78.13M
Inventory $7.63M $7.71M $6.51M $5.52M $5.52M
Other Current Assets $8.22M $8.30M $8.44M $15.35M $15.35M
Total Non-Current Assets $37.01M $31.16M $28.55M $30.18M $30.18M
Net PPE $3.25M $3.38M $3.52M $3.67M $3.67M
-Gross PPE $3.25M $3.38M $3.52M $7.14M $7.14M
Other Non-Current Assets $33.76M $27.78M $25.03M $26.51M $26.51M
Total Liabilities $692.66M $671.35M $642.08M $697.32M $697.32M
Total Current Liabilities $174.90M $153.78M $125.04M $132.04M $132.04M
Payables $11.11M $5.36M $6.37M $4.98M $4.98M
-Accounts Payable $11.11M $5.36M $6.37M $4.98M $4.98M
Current Accrued Expenses $108.21M $97.16M $75.78M $76.82M $76.82M
Short-Term Debt and Capital Lease Obligation $673,000.00 $670,000.00 $667,000.00 $648,000.00 $648,000.00
-Current Capital Lease Obligation $673,000.00 $670,000.00 $667,000.00 $648,000.00 $648,000.00
Other Current Liabilities $40.52M $37.28M $33.02M $34.75M $34.75M
Total Non-Current Liabilities $517.76M $517.57M $517.03M $565.27M $565.27M
Long Term Debt and Capital Lease Obligation $167.28M $166.44M $165.64M $211.15M $211.15M
-Long Term Debt $165.54M $164.59M $163.68M $209.09M $209.09M
-Long Term Capital Lease Obligation $1.74M $1.86M $1.96M $2.07M $2.07M
Other Non-Current Liabilities $350.47M $351.13M $351.40M $354.12M $354.12M
Total Equity -$347.64M -$344.27M -$336.96M -$438.17M -$438.17M
Stockholders' Equity -$347.64M -$344.27M -$336.96M -$438.17M -$438.17M
Capital Stock $8,000.00 $8,000.00 $7,000.00 $6,000.00 $6,000.00
-Common Stock $8,000.00 $8,000.00 $7,000.00 $6,000.00 $6,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.20B $1.19B $1.18B $1.05B $1.05B
Retained Earnings -$1.55B -$1.53B -$1.51B -$1.48B -$1.48B
Less: Treasury Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Accumulated Depreciation – – – -$3.48M -$3.48M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $1.84M -$1.93M -$15.65M -$166.78M -$5.00M
Net cash flow from continuing operations $1.84M -$1.93M -$15.65M -$166.78M -$5.00M
Net Income from Continuing Operations -$13.90M -$17.58M -$30.37M -$221.25M -$21.15M
Gain/Loss from Continuing Operations $0.00 $0.00 $829,000.00 – –
Depreciation & Depletion & Amortization $120,000.00 $114,000.00 $110,000.00 $633,000.00 $128,000.00
Other Non-Cash Items $4.73M $6.19M $6.70M $37.22M $6.90M
Change in Working Capital $4.05M $2.63M $1.55M -$12.38M $4.05M
-Change in Receivables -$10.18M -$16.70M -$2.60M -$39.33M -$22.34M
-Change in Inventory -$6.34M -$3.96M $665,000.00 -$11.78M $2.00M
-Change in Prepaid Assets $81,000.00 $132,000.00 $6.92M $5.51M -$2.13M
-Change in Payables and Accrued Expense $20.98M $23.16M -$3.28M $34.23M $27.64M
-Change in Other Current Assets -$478,000.00 $0.00 -$171,000.00 -$1.22M -$1.22M
-Change In Other Working Capital -$8,000.00 -$5,000.00 $10,000.00 $222,000.00 $90,000.00
Net cash flow from investing -$110,000.00 -$44,000.00 -$61,000.00 -$229,000.00 -$87,000.00
Net Cash Flow from Continuing Investing Activities -$110,000.00 -$44,000.00 -$61,000.00 -$229,000.00 -$87,000.00
Net PPE Purchase and Sale -$110,000.00 -$44,000.00 -$61,000.00 -$229,000.00 -$87,000.00
Financing Cash Flow $351,000.00 $3.55M $66.64M -$288,000.00 -$97,000.00
Net Cash Flow from Continuing Financing Activities $351,000.00 $3.55M $66.64M -$288,000.00 -$97,000.00
Net Issuance Payments Of Debt $0.00 $0.00 -$55.80M $0.00 $0.00
Net Common Stock Issuance $0.00 $0.00 $121.97M $0.00 $0.00
Proceeds from Stock Option Exercised $372,000.00 $3.55M $591,000.00 $1.64M $1.27M
Net Other Financing Charges -$21,000.00 $0.00 -$128,000.00 -$1.93M -$1.36M
Ending Cash Balance $187.42M $185.34M $183.77M $132.83M $132.83M
Net Change in Cash $2.08M $1.58M $50.93M -$167.29M -$5.19M
Beginning Cash Balance $185.34M $183.77M $132.83M $300.13M $138.02M
Free Cash Flow $1.73M -$1.97M -$15.71M -$167.00M -$5.09M

Discussion

No comments yet — be the first to weigh in on PHAT.

Sign in to join the discussion.

Scroll to Top